Skip to main content
Astellas Pharma Inc. logo

Astellas Pharma Inc. — Investor Relations & Filings

Listed IPO Jan 2000
Ticker · 4503 ISIN · JP3942400007 LEI · 529900IB708DY2HBBB35 T Manufacturing
Open in API
Filings indexed 132 across all filing types
Latest filing 2026-04-27 Earnings Release
Country JP Japan
Listing T 4503 · 7 venues

About Astellas Pharma Inc.

https://www.astellas.com/en

Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving human health by turning innovative science into value for patients. The company's core activities encompass the research, development, manufacture, and commercialization of novel pharmaceutical products. Astellas focuses on pioneering transformative therapies in disease areas with high unmet medical needs, including oncology, ophthalmology, urology, immunology, and women's health. Through its patient-centric approach and robust research and development programs, the company aims to deliver innovative healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
2026年３月期 決算短信［IFRS］（連結）
Earnings Release Classification · 100% confidence The document is a 'Kessan Tanshin' (Financial Results Summary) for Astellas Pharma for the fiscal year ending March 2026. It contains detailed financial performance data, including consolidated income statements, balance sheets, cash flow statements, and forward-looking guidance. While it is a summary report, it provides substantive financial data and analysis, fitting the definition of an Earnings Release (ER) in the context of Japanese corporate filings, as it is the primary announcement of financial results for the period. FY 2026
2026-04-27 Japanese
役員人事に関するお知らせ
Board/Management Information Classification · 100% confidence The document is titled '役員人事に関するお知らせ' (Notice regarding personnel changes of officers) and details the nomination of candidates for the Board of Directors and Audit and Supervisory Committee for Astellas Pharma Inc. It lists current and incoming directors, their roles, and biographical information for new candidates. This content directly matches the definition for 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-04-27 Japanese
2026年３月期 決算短信［IFRS］（連結）
Regulatory Filings
2026-04-27 Japanese
2026年３月期 第３四半期決算短信［IFRS］（連結）
Regulatory Filings
2026-02-04 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-5-2, Paragraph 1. It confirms the accuracy of the contents of a semi-annual report (Hankishokokusho) for the period ending September 30, 2025. Since this is a regulatory filing confirming the accuracy of financial reporting and does not fit into the specific categories of the reports themselves (like 10-K or IR), it is classified as a general regulatory filing.
2025-11-06 Japanese
半期報告書－第21期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Astellas Pharma Inc. with the Kanto Local Finance Bureau in Japan. It covers the interim accounting period from April 1, 2025, to September 30, 2025. It contains detailed financial statements, management analysis (MDA), and business performance data. In the context of Japanese regulatory filings, this corresponds to an Interim/Quarterly Report (IR). H1 2026
2025-11-06 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.